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Introduction
Epithelial to mesenchymal transition (EMT) enables the migration of epithelial cells into connective tissues, a critical process for embryonic development (1) . In cancer, it has been shown that epithelial tumor cells exploit EMT to detach from the primary tumor mass and disseminate into the surrounding stroma (2) . It has also been shown that epithelial cells can be endowed with stem-like properties through EMT (3) . Such findings demonstrate that EMT plays a key role in the progression of epithelial tumors (4, 5) . However, the cellular source and the nature of the signals that turn on and off the EMT cascade in cancer remain largely unknown. Such knowledge is critical for the understanding of the pathobiology of local invasion and metastasis of epithelial tumors, and may unveil novel therapeutic targets for this type of malignancy.
Loss of E-cadherin, a hallmark of EMT, is an important step in the progression of papilloma to invasive carcinoma (6) . It has been recently shown that EMT is modulated by transcription factors that regulate E-cadherin, e.g. Snail (3,7), Twist (8) , and ZEB1 (9) . For example, Snail controls EMT by repressing E-cadherin expression in development and cancer (10) . Twist is required for EMT and breast cancer metastasis (8) . In general, expression of these transcription factors is correlated with increased invasiveness-metastasis and poorer clinical prognosis (11) .
EGF is a well-known mitogen that plays important roles in cell proliferation survival in physiological settings and in cancer (12) (13) (14) . Continuous EGF treatment has been shown to downregulate E-cadherin expression and results in loss of cell-cell adherence junctions (15) .
EGF treatment enhances tumor progression and induces EMT in breast cancer cells and cervical cancer cells (13, 14) . Notably, a recent study showed that the overexpression of EGF receptor 4 (EGFR) results in the enrichment of a subset of esophageal cells that is capable of undergoing EMT in response to TGF-ȕ through ZEB transcription factor (16) . However, the cellular source of EGF within the tumor microenvironment remains unclear.
Mounting evidence demonstrates that epithelial tumors contain a small sub-population of cells with stem-like and/or progenitor characteristics (17) (18) (19) . These cells are highly tumorigenic, exhibit self-renewal, and are capable of differentiating into complex new tumors (20) . The origin of these cancer stem cells remains unclear. However, exciting new evidence suggests that EMT allows for the generation of cells with stem cell properties in tumor models (3, 21, 22) .
We have showed that EGF secreted by endothelial cells induces motility and protects human squamous cell carcinoma (SCC) against anoikis (23) . In addition, we have shown that endothelial cell-secreted factors enhance the survival, self-renewal and tumorigenicity of cancer stem cells (24) . Here, we hypothesized that EGF secreted by endothelial cells enables tumor cell motility by inducing EMT and by endowing SCC cells with stemness. This work showed that endothelial cell-secreted EGF induces Snail through the PI3k-Akt pathway and induces EMT of squamous cell carcinoma cells, as shown by downregulation of epithelial markers (E-cadherin, Desmoplakin), upregulation of mesenchymal markers (Vimentin, N-Cadherin), induction of cell motility and acquisition of stem-like properties (expression of ALDH and CD44) and growth as non-adherent orospheres. Notably, specific silencing of EGF in endothelial cells slowed down tumor growth and decreased the fraction of stem-like cells in xenograft models. Collectively, these data demonstrate that signals secreted by tumor-associated endothelial cells enhance the aggressive behavior (motility and stemness) of epithelial cancer cells. 
Materials and Methods
Cell culture: University of Michigan squamous cell carcinoma (UM-SCC) cells, UM-SCC-1,   UM-SCC-11A, UM-SCC-11B, UM-SCC-14A, UM-SCC-14B, UM-SCC-17A, UM-SCC-17B,   UM-SCC-22A, UM-SCC-22B, UM-SCC-74A and UM-SCC-74B (Tissue Biorepository, University of Michigan Head and Neck SPORE) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 100 U/ml penicillin, and 100 ȝg/ml streptomycin. All cell lines were genotyped and authenticated prior to use in the experiments included in this manuscript. Pooled primary human dermal microvascular endothelial cells (HDMEC; Lonza, Walkersville, MD) were cultured in endothelial growth medium-2 for microvascular cells (EGM2-MV; Lonza). Cancer cells were serum starved overnight, and treated with 0-50 ng/ml rhEGF, anti-human EGF neutralizing antibody (Cat.
MAB236; R&D Systems, Minneapolis, MN) for indicated time points. Alternatively, HDMEC were cultured in serum-free medium (EBM2, Lonza) for 24 hours, and the supernatants were collected as endothelial cell conditioned medium (EC CM). Notably, EGF levels in culture supernatants were normalized to cell number for all experiments included here. SCC were starved overnight Affinity-purified second antibodies conjugated with horseradish peroxidase (Jackson Laboratories, West Grove, PA) were used, and immunoreactive proteins were visualized by SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, Rockford, IL) and exposed to x-ray film.
Stem cell staining and flow cytometry analysis: Starved SCC cells were treated with 0-50 ng/ml EGF, EC CM or unconditioned medium for 24 hours. Stemness was assessed by ALDH (aldehyde dehydrogenase) activity and CD44 expression, as we showed (24) . Briefly, cells were collected and stained with Aldefluor (Aldagen Inc, Durham, NC) using diethylaminobenzaldehyde Orosphere assay: UM-SCC-1, UM-SCC-22A or UM-SCC-22B cells (1,000-3,000) were cultured in ultra-low attachment plates (Corning Inc., Corning, NY) with serum-free medium containing 0-50 ng/ml EGF, EC CM, or unconditioned medium for 7-15 days, as we showed (25) .
Orospheres, defined as non-adherent spheres of 25 cells, were photographed and counted under light microscopy. 
Results

Endothelial cell-secreted EGF induces EMT of squamous cell carcinoma cells
A hallmark of cells undergoing EMT is the loss of epithelial markers (e.g. E-cadherin, Desmoplakin) and concomitant acquisition of mesenchymal markers (e.g. Vimentin, N-cadherin) (26) . We analyzed the primary head and neck squamous cell carcinoma (HNSCC) of a patient that presented with distant metastases 1 year after surgical removal of the primary tumor ( Figure   1A ). We observed a group of tumor cells approaching a blood vessel and a cluster of tumor cells EGF has been strongly correlated with the aggressiveness of epithelial cancers (13, 14) . We observed that recombinant human EGF induces a change in HNSCC morphology, loosing their typical cobblestone appearance and assuming a more elongated, fibroblast-like, morphology ( Figure 2A) . Surprisingly, the expression levels of EGF in head and neck squamous cell Figure 1C- 
E).
To further evaluate the effect of EGF on SCC motility, we performed the in vitro scratch assay (28) . It revealed that EGF, or the full complement of endothelial cell-secreted factors, significantly induce tumor cell motility and speed up closure of the "scratch" (Figure 3 ; Suppl. Figure 2) .
Collectively, these data demonstrate that endothelial cell-secreted EGF induces EMT in squamous cell carcinoma cells.
Endothelial cell-secreted EGF induces EMT through PI3K/Akt signaling
To evaluate the effect of endothelial cell-secreted EGF on the activity of signaling pathways that play a key role in HNSCC survival and motility (23) tumor cells ( Figure 4H and I). These data suggest that PI3K/Akt signaling plays an important role in the EMT mediated by EGF.
Endothelial cell-secreted EGF endows epithelial tumor cells with stem-like characteristics
To evaluate a potential mechanistical link between endothelial cell-secreted EGF, EMT, and acquisition of stem cell features, we seeded SCC cells in ultra-low attachment plates and cultured them in serum-free medium with or without EGF, or in endothelial cell conditioned medium, for 7-14 days ( Figure 5 ). EGF supplementation, or treatment with endothelial cell-secreted factors, induced a significant increase in the number of orospheres when compared to controls (Figure 5A-C) . Notably, recombinant human EGF or the full milieu of growth factors secreted by endothelial cells induced expression of Bmi-1 ( Figure 5D and E), an important regulator of self-renewal and stemness (29, 30) . The Bmi-1 activation in response to the endothelial cell growth factor milieu was strictly dependent on EGF ( Figure 5E ). Collectively, these data suggest that endothelial cell-secreted factors enhanced the fraction of ALDH+CD44+ cells in an EGF-dependent manner via the PI3K/Akt signaling pathway.
Endothelial cell-secreted EGF enhances tumor growth and cancer stem cell fraction
To evaluate the effect of endothelial cell-secreted EGF on the pathobiology of HNSCC, we (33) . Indeed, cell plasticity may allow the conversion of normal and neoplastic non-stem cells into a stem-like cell (34) . MET often converts the disseminated mesenchymal cancer cells back to a more differentiated, epithelial cell state (35) . We speculate that once the SCC cells have moved through the connective tissue, and EMT is no longer a favorable trait, these cells default back to their original epithelial phenotype.
ALDH is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome for patients with cancer (36, 37) . CD44-positive cells have the properties of cancer stem cells in human head and neck SCC (20) . Notably, CD44 is a strong predictor of local recurrence after radiotherapy in larynx cancer (38) . We have successfully used the combination of ALDH activity and CD44 expression to identify a small sub-population of highly tumorigenic cancer stem cells (24) . Here, we observed that endothelial cell-secreted EGF determines the percentage of cancer stem cells (ALDH+CD44+) in vitro and in vivo. We also observed that endothelial cell-EGF levels correlate directly with the expression of the self-renewal marker Bmi-1 in epithelial tumor cells and with xenograft tumor growth. Interestingly, the high levels of expression of ALDH1 and CD44 observed in the cluster of tumor cells within the blood vessel of the primary human HNSCC presented here suggest that these cells have acquired stemness.
Therefore, these cells may be highly tumorigenic and primed to establish metastatic foci at distant sites, as shown in breast cancer (36, 37, 39) . Collectively, these observations suggest that endothelial cell-secreted factors (EGF) are likely involved in metastatic spread by attracting We observed here that endothelial cell-secreted factors, and particularly EGF, activate major signaling pathways in squamous cell carcinoma cells, i.e. STAT3, ERK and PI3K/Akt. We have previously shown that these pathways regulate head and neck tumor cell proliferation, migration, and anoikis resistance (23) . The induction of cell survival may be responsible, at least in part, for the ability of epithelial tumor cells to leave their nests and migrate through connective tissue.
Notably, EGF signaling through PI3K/Akt appears to be the primary pathway for the induction of the Snail. This observation suggests that EGF-induced EMT is mediated by PI3K/Akt signaling and induction of Snail activity, a major transcriptional regulator of EMT and metastases (40, 41) .
Collectively, these data suggest that EGF enables epithelial tumor cell invasion through the connective tissue via EMT while protecting these cells against anoikis. 
